Immunotherapy of cancer
Invited discussant abstracts 1052PD, 1053PD, 1054PD and 1056PD
Date
10 Oct 2016Session
Immunotherapy of cancerPresenters
Suzy SchollAuthors
S. SchollAuthor affiliations
- Oncology, Institut Curie, 75005 - Paris/FR
Resources
Login to access the resources on OncologyPRO.
If you do not have an ESMO account, please create one for free.
Resources from the same session
3042 - Changes in serum IL8 levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small cell lung cancer patients
Presenter: Miguel Sanmamed
Session: Immunotherapy of cancer
Resources:
Abstract
Slides
1387 - Active8: A randomized, double-blind, placebo-controlled study of chemotherapy plus cetuximab in combination with motolimod immunotherapy in patients with recurrent or metastatic squamous cell carcinoma of the head and neck
Presenter: Ezra Cohen
Session: Immunotherapy of cancer
Resources:
Abstract
Slides
2980 - Baseline tumor T cell receptor (TcR) sequencing analysis and neo antigen load is associated with benefit in melanoma patients receiving sequential nivolumab and ipilimumab
Presenter: Jeffrey Weber
Session: Immunotherapy of cancer
Resources:
Abstract
3047 - Ongoing complete remissions in phase 1 of ZUMA-1: a phase 1-2 multi-center study evaluating the safety and efficacy of KTE-C19 (anti-CD19 CAR T cells) in patients with refractory aggressive B cell non-Hodgkin lymphoma (NHL)
Presenter: Frederick Locke
Session: Immunotherapy of cancer
Resources:
Abstract
Slides
Invited discussant abstracts 1047O and 1048O
Presenter: Inge-Marie Svane
Session: Immunotherapy of cancer
Resources:
Slides
1880 - A phase 1b study (SCORES) assessing safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of durvalumab combined with AZD9150 or AZD5069 in patients with advanced solid malignancies and SCCHN
Presenter: David Hong
Session: Immunotherapy of cancer
Resources:
Abstract
2130 - Combination of MEDI0680, an anti-PD-1 antibody, with durvalumab, an anti-PD-L1 antibody: A phase 1, open-label study in advanced malignancies
Presenter: Omid Hamid
Session: Immunotherapy of cancer
Resources:
Abstract
2428 - Interim safety and clinical activity in patients with advanced NSCLC from a multi-cohort phase 1 study of ramucirumab (R) plus pembrolizumab (P)
Presenter: Roy Herbst
Session: Immunotherapy of cancer
Resources:
Abstract
1903 - The MITCI (phase 1b) study: a novel immunotherapy combination of coxsackievirus A21 and ipilimumab in patients with advanced melanoma
Presenter: Brendan Curti
Session: Immunotherapy of cancer
Resources:
Abstract
Invited discussant abstracts 1049PD, 1050PD, 1051PD and LBA38
Presenter: Thomas Powles
Session: Immunotherapy of cancer
Resources:
Slides
Webcast